Liver Cancer Trial, Recruiting NCT07252323 Sponsor: Yonsei University Condition: Liver Cancer
Back to Liver Cancer

Liver Cancer Trial, Recruiting

NCT07252323
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 20 or older who have been diagnosed with liver cancer (hepatocellular carcinoma), confirmed by imaging or tissue testing
  • People who have had a previous TARE treatment (a type of internal radiation therapy for liver cancer) and still have remaining cancer, or whose cancer has come back or grown in or near the treated area, and whose doctors have decided further treatment is needed after at least 6 months of follow-up
  • People whose liver is functioning at a level classified as Child-Pugh Class A (score 5–6) or Child-Pugh Class B (score of 7 only) — a measure of liver health (confirm with trial site)
  • People whose cancer falls within the size and location range that the treatment used in this trial can target
  • People who have enough healthy liver tissue remaining to preserve liver function during treatment
  • People whose liver enzyme levels (AST and ALT) are less than 5 times the upper limit of the normal range
  • People who do not have a blood clotting disorder
  • People with an ECOG performance status of 2 or lower — meaning they are able to carry out some daily activities independently
  • Women who are not pregnant, or women of childbearing age who are using appropriate contraception
  • People without other serious underlying health conditions that would significantly affect survival
  • People who have been fully informed about the trial and have signed a consent form

Who may not be able to join:

  • People who have previously received external beam radiation therapy to the liver
  • People who have an active, unresolved infection at the time of enrolment
  • People who currently have, or have had within the last 5 years, another advanced cancer (other than the liver cancer being treated)
  • People who have previously had a liver transplant
  • People whose treating radiation oncologist considers the planned treatment to be inappropriate or unsafe for them

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
12 November 2024
Est. completion
1 November 2026

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Objective Response Rate (ORR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov